AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00460057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
Study NCT03938077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storytelling 4 Empowerment
Description: S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
Study NCT03877250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Treatment Biopsy
Description: Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
Study NCT03877250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: On-Treatment Biopsy
Description: All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed \~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
Study NCT03877250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy at Disease Progression
Description: All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
Study NCT03877250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Blood-Based Studies
Description: All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
Study NCT03672422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
Study NCT03672422 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient questionnaires
Description: Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
Study NCT03672422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: 2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
Study NCT03672422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine sample
Description: 50 ml of urine in collection container.
Study NCT04052568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
Study NCT00846885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: 100 mg Tablet
Study NCT00846885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex®
Description: 100 mg Tablet
Study NCT02160704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enclomiphene citrate
Description: 25 mg daily for 16 weeks
Study NCT02160704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily for 16 weeks
Study NCT04609059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Study NCT04609059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Study NCT01096355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT03478163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeFAZolin 1000 MG
Description: Cefazolin 1000 mg every 8 hours for 3 doses
Study NCT03478163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 900 MG in 6 ML Injection
Description: Clindamycin 900 mg every 8 hours for 3 doses
Study NCT02715661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: six-month interval of exercise
Study NCT02185209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Place capsule to mimic antibiotics
Study NCT02185209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Sandoz
Description: Tablet 500 mg amoxicillin Sandoz three times a day
Study NCT02185209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Sanofi
Description: 400 mg metronidazole Sanofi administered three times a day (TID)
Study NCT02185209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin Meda
Description: 1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
Study NCT02761746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESA
Description: MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
Study NCT00279110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Description: Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
Study NCT04370288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
Description: A mixture of MCN will be injected to covid-19 patients.
Study NCT00154076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
Study NCT00154076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
Study NCT00698464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Single subcutaneous injection of 600 µg of Pasireotide.
Study NCT00901030 — intervention group
Intervention type: PROCEDURE
Intervention: Blood drawn
Description: Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
Study NCT02580396 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CanADVICE+® (smart phone app)
Description: The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
Study NCT00786396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy
Description: Daily observation of subjects taking their HIV medications
Study NCT01521819 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iray
Description: The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
Study NCT01521819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Intravitreal injection of Lucentis as needed.
Study NCT01251120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
Study NCT01251120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARD
Description: Non-biologic DMARDs (including methotrexate) according to current best practice
Study NCT04197726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sbeIIa/b white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Study NCT04197726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sbeIIa/b white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Study NCT04197726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Study NCT04197726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Study NCT03187977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
Study NCT01859078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01859078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study NCT02785679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cow's milk formula
Description: addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
Study NCT01473316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Single oral dose
Study NCT01473316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Repeating Oral Dose
Study NCT03367715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: study treatment on Day 1 with one dose of nivolumab 3 mg/kg
Study NCT03367715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: study treatment on Day 1 with one dose of ipilimumab 1mg/kg
Study NCT03367715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
Study NCT04641780 — intervention group
Intervention type: DRUG
Intervention: Brexpiprazole
Description: For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment.
Study NCT02708017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided bilateral subcostal TAP block
Description: ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
Study NCT02708017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided bilateral posterior TAP block
Description: ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
Study NCT00294385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00294385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Docetaxel
Description: Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
Study NCT00294385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
Study NCT03956368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: 20mg (every evening orally) for 8 weeks.
Study NCT03956368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 20mg (every evening orally) for 8 weeks.
Study NCT02155036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
Study NCT01037907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleneva TM BGC20-0134
Description: Placebo or 5 g dose
Study NCT01037907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or 5 g dose
Study NCT00619905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT00619905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACZ885
Study NCT04641507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil versus tamsulosin as MET
Description: 166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
Study NCT01558427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance
Description: Active clinical surveillance
Study NCT01558427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Description: Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
Study NCT02627352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse Transscleral Cyclophotocoagulation
Description: In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
Study NCT01772004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Study NCT00628108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine 1.25 mg
Description: Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
Study NCT00628108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral liquid once a day for two weeks
Study NCT04687982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified donor lymphocytes infusion (mDLI)
Description: The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient.
Study NCT02052258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01217151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic monitoring
Description: Hemodynamic monitoring based on the NICOM device
Study NCT01217151 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual treatment
Description: Hemodynamic monitoring based on common practice
Study NCT02019420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV 200 mg once daily
Study NCT02019420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid IV 600 mg twice daily
Study NCT02294123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 tortillas and white bread
Description: Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
Study NCT03566433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tep surgery for inguinal hernia
Description: TEP surgery
Study NCT03566433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein
Description: Lichtenstein surgery for inguinal hernia
Study NCT01791023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: 30 minutes of aerobic exercise on treadmill with moderate intensity.